Using Feature Models for Distributed Deployment in Extended Smart Home Architecture

Nowadays, smart home is extended beyond the house itself to encompass connected platforms on the Cloud as well as mobile personal devices. This Smart Home Extended Architecture (SHEA) helps customers to remain in touch with their home everywhere and any time. The endless increase of connected devices in the home and outside within the SHEA multiplies the deployment possibilities for any application. Therefore, SHEA should be taken from now as the actual target platform for smart home application deployment. Every home is different and applications offer different services according to customer preferences. To manage this variability, we extend the feature modeling from software product line domain with deployment constraints and we present an example of a model that could address this deployment challenge

Software Evolution Multi-View : From the Smart Home to the Cloud

National audienceThe alliance between the Smart Home embedded devices e.g., gateways, tablets, media server, home automation boxes, and the Cloud for the Smart Home Service hosting becomes a proven reality. Taking into account Cloud to overcome the embedded resources limitation e.g. for reducing the bill of material for a new customer, or to offer service flexibility and scalability is a very appealing goal. In order to take benefit of these opportunities, selecting an optimal deployment of Service applications in this distributed platform is required. We introduce a new approach based on feature modelling which has been originally introduced for SPL for expressing the deployment constraints in spite of the Smart Home wide variability. As a first step we show how to get an optimized first deployment of any given set of Home Services. In a second step we will address the deployment adaptation at runtime in response to environment or software evolution

Prescription of Proton Pump Inhibitors in Elderly Subjects in Real Life: A Retrospective Study in a Gastroenterology Department

The proton-pump inhibitor (PPI) is an effective and widely used treatment but may cause side effects, especially for the elderly. Materials and methods: this is a cross-sectional study including 45 patients older than 65 years, followed at our outpatient and treated with PPIs for at least a year. The indication for PPI, the results of any endoscopy, and the quality of the tolerance of these molecules is specified by the data folder. During the consultation, we conducted an interrogation to an update of the history and medications to our patients and a type checking of the molecule, the dose, and the quality of the observance. Results: patients were divided into 32 women and 13 men with a mean age of 75 ± 7 years (65–92). The average length of PPI use was 6 ± 4 years (1–16) with a consumption of a double dose for at least 1 year in 28.8% of cases. The prescribed dose was higher than the recommended dose in at least 15.5% of cases. PPIs were well tolerated. One patient had presented a microscopic colitis, revealed by diarrhea regressed after discontinuation of PPIs. Conclusion: PPIs were prescribed in elderly subjects by gastroenterologists, in a university center, with a high dose and long. In our series, this treatment is well tolerated in the elderly

Gastrointestinal stromal tumors: epidemiological, clinical and therapeutic profile in Marrakech University Hospital

Les tumeurs stromales gastro-intestinales ou GIST sont des tumeurs mésenchymateuses rares (1 à 3 % des tumeurs malignes gastro-intestinales). Elles font l’objet de multiples controverses. Nous rapportons une étude rétrospective portant sur 17 cas de tumeurs stromales gastro-intestinales confirmées histologiquement et à l'immunohistochimie, colligés au CHU Mohammed VI. L’âge moyen des patients était de 59 ans (de 29 à 80 ans). La symptomatologie révélatrice était une douleur abdominale dans la majorité des cas (49 %), une masse abdominale retrouvée chez 35 % des patients et une hépatomégalie dans 2 cas. Il s’agissait de 6 cas de tumeurs gastriques, 4 cas de tumeurs mésentériques, 4 cas de tumeurs jéjunales, et 3 cas de tumeurs rectales. Quinze patients ont été traités par exérèse chirurgicale complète. A l’histologie, l’expression du marqueur C KIT à était présente dans 100 % des cas. Dans 13 cas, il s’agissait de tumeurs localisées, deux patients présentaient d’emblée des tumeurs localement avancées et deux autres avaient des métastases hépatiques au moment du diagnostic. Un traitement médicamenteux à base d'Imatinib était entrepris dans les tumeurs classées de haut grade de malignité, dans 6 cas en adjuvant, et dans 2 cas en néoadjuvant. Sur un recul moyen de 3 ans, la survie moyenne était de 88 % à 3 ans et on notait 8 cas de rémission complète, 3 cas de rémission partielle, 2 cas de récidive tumorale et 2 cas de décès.Stromal tumors or GIST (gastrointestinal mesenchymal tumors) are rare (1-3% of gastro-intestinal malignancies). They are a subject of controversy. We report a retrospective study of 17 cases of gastrointestinal stromal tumors confirmed histologically and immuno-histochemically, collected at the University Hospital Mohammed VI. The average age of patients was 59 years, (29-80 years). The symptoms were abdominal pain in most cases (49%), abdominal mass found in 35% of our patients and hepatomegaly in 2 cases. There were 6 cases of gastric tumors, 4 cases of mesenteric tumors, 4 cases of jejunal tumors, and 3 cases of rectal tumors. Fifteen patients were treated with complete surgical resection. A histological marker expression C KIT was present in 100% of cases. In 13 cases tumors were localized, 2 patients had locally advanced tumors immediately and 2 others had liver metastases at diagnosis. Medication with Imatinib was initiated in the tumors classified high-grade malignancy in 6 cases in adjuvant and neoadjuvant in 2 cases. On a mean of 3 years, the 3-year survival was 88% and we had 8 cases of complete remission, 3 cases of partial remission, 2 cases of tumor recurrence and 2 deaths